A NeurologyLive news article highlights findings from the Bio-Hermes study that led to the development of Cognivue’s new prediction metric, the Cognivue Amyloid Risk Measure (CARM).* In the piece, Dr. James Galvin, MD, MPH, Chief Scientific Officer at Cognivue, shares clinical insights on how CARM, together with the overall Cognivue Clarity^® score, provides meaningful support in predicting amyloid positivity.

News article and an explanatory video published on NeurologyLive. In it, Dr. James Galvin, MD, MPH, Chief Scientific Officer at Cognivue, gives an informative explanation of the clinical application of Cognivue’s new prediction metric, the Cognivue Amyloid Risk Measure (CARM).*

Neuroscience technology company Cognivue, Inc. has hired Ernest Fung, PsyD, ABPP, as vice president of Clinical and Medical Affairs. A distinguished clinical and forensic neuropsychologist, he brings a wealth of experience to Cognivue’s executive leadership team. Cognivue President and CEO Tom O’Neill said, “Dr. Fung’s rare blend of business and clinical experience, combined with his specialization in cognitive performance assessment and knowledge of neurodegenerative disorders as well as traumatic brain injury, will further advance Cognivue’s innovative work. We are privileged to welcome him to our veteran team...